218 related articles for article (PubMed ID: 32162988)
1. Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
Jing M; Bi XJ; Yao XM; Cai F; Liu JJ; Fu M; Kong L; Liu XZ; Zhang L; He SY; Jia LQ; Li XT
Drug Dev Ind Pharm; 2020 Apr; 46(4):621-634. PubMed ID: 32162988
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition.
Cai FY; Yao XM; Jing M; Kong L; Liu JJ; Fu M; Liu XZ; Zhang L; He SY; Li XT; Ju RJ
J Liposome Res; 2021 Jun; 31(2):113-129. PubMed ID: 32200703
[TBL] [Abstract][Full Text] [Related]
3. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
[TBL] [Abstract][Full Text] [Related]
4. The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice.
Zhang L; Kong L; He SY; Liu XZ; Liu Y; Zang J; Ju RJ; Li XT
Life Sci; 2021 Nov; 285():120013. PubMed ID: 34614418
[TBL] [Abstract][Full Text] [Related]
5. Development of R
Liu JJ; Tang W; Fu M; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1947-1960. PubMed ID: 31079495
[TBL] [Abstract][Full Text] [Related]
6. RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
Kong L; Cai FY; Yao XM; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT
Cancer Sci; 2020 Feb; 111(2):621-636. PubMed ID: 31777993
[TBL] [Abstract][Full Text] [Related]
7. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137
[TBL] [Abstract][Full Text] [Related]
8. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.
Song XL; Ju RJ; Xiao Y; Wang X; Liu S; Fu M; Liu JJ; Gu LY; Li XT; Cheng L
Int J Nanomedicine; 2017; 12():7433-7451. PubMed ID: 29066893
[TBL] [Abstract][Full Text] [Related]
9. Functional vinorelbine plus schisandrin B liposomes destroying tumor metastasis in treatment of gastric cancer.
Li XY; Shi LX; Yao XM; Jing M; Li QQ; Wang YL; Li QS
Drug Dev Ind Pharm; 2021 Jan; 47(1):100-112. PubMed ID: 33295825
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer.
Wang Y; Fu M; Liu J; Yang Y; Yu Y; Li J; Pan W; Fan L; Li G; Li X; Wang X
Int J Nanomedicine; 2019; 14():4071-4090. PubMed ID: 31239668
[No Abstract] [Full Text] [Related]
11. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
Ju RJ; Zeng F; Liu L; Mu LM; Xie HJ; Zhao Y; Yan Y; Wu JS; Hu YJ; Lu WL
Int J Nanomedicine; 2016; 11():1131-46. PubMed ID: 27042063
[TBL] [Abstract][Full Text] [Related]
12. Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathway.
Jiang Y; Zhang Q; Bao J; Du C; Wang J; Tong Q; Liu C
Biomed Pharmacother; 2015 Aug; 74():77-82. PubMed ID: 26349966
[TBL] [Abstract][Full Text] [Related]
13. Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition.
Liu Z; Zhang B; Liu K; Ding Z; Hu X
PLoS One; 2012; 7(7):e40480. PubMed ID: 22848381
[TBL] [Abstract][Full Text] [Related]
14. Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer.
Fu M; Tang W; Liu JJ; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
J Drug Target; 2020 Mar; 28(3):245-258. PubMed ID: 31462111
[TBL] [Abstract][Full Text] [Related]
15. Effects of VEGFR1
Meng D; Meng M; Luo A; Jing X; Wang G; Huang S; Luo M; Shao S; Zhao X; Liu R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):411-427. PubMed ID: 30483898
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma.
Liu S; Zhang SM; Ju RJ; Xiao Y; Wang X; Song XL; Gu LY; Cheng L; Li XT; Chen GR
Eur J Pharm Sci; 2017 Aug; 106():185-197. PubMed ID: 28583810
[TBL] [Abstract][Full Text] [Related]
17. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer.
Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Zhao Y; Yan Y; Hu YJ; Wu JS; Lu WL
Oncotarget; 2015 Nov; 6(34):36625-42. PubMed ID: 26429872
[TBL] [Abstract][Full Text] [Related]
18. Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC.
Kong L; Zhang SM; Chu JH; Liu XZ; Zhang L; He SY; Yang SM; Ju RJ; Li XT
Int J Nanomedicine; 2020; 15():6451-6468. PubMed ID: 32922011
[TBL] [Abstract][Full Text] [Related]
19. Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer.
Ju RJ; Cheng L; Peng XM; Wang T; Li CQ; Song XL; Liu S; Chao JP; Li XT
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):616-628. PubMed ID: 29381101
[TBL] [Abstract][Full Text] [Related]
20. Efficacy in Treating Lung Metastasis of Invasive Breast Cancer with Functional Vincristine Plus Dasatinib Liposomes.
Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Lu WL
Pharmacology; 2018; 101(1-2):43-53. PubMed ID: 28988243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
